Welcome to our dedicated page for Elevation Oncolo SEC filings (Ticker: ELEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Elevation Oncology can feel overwhelming—every 10-K details cash runway for ADC trials, each 8-K flags fresh study data, and Form 4s reveal when executives trade shares. If you have ever typed “Elevation Oncology SEC filings explained simply” or “where to find Elevation Oncology quarterly earnings report 10-Q filing,” you already know the challenge.
Stock Titan solves it. Our AI instantly converts Elevation Oncology’s dense disclosures into clear language, highlighting R&D spend, Claudin 18.2 and HER3 program updates, and milestone payments so you can focus on decisions, not page counts. Whether you need the Elevation Oncology annual report 10-K simplified, a quick read-out of the latest Elevation Oncology 8-K material events explained, or real-time alerts on Elevation Oncology Form 4 insider transactions, we have you covered.
All filings arrive seconds after EDGAR posts, organized by form type and paired with:
- AI-powered summaries that decode complex clinical terminology
- Red-flag detection on liquidity, trial risks, and dilution
- Side-by-side views of prior quarters for easy trend analysis
Common questions answered naturally: “How do I monitor Elevation Oncology executive stock transactions Form 4? Click the Insider tab. “Need the latest Elevation Oncology earnings report filing analysis? Open our 10-Q dashboard.” From Elevation Oncology proxy statement executive compensation tables to “understanding Elevation Oncology SEC documents with AI,” every angle is covered in one place.
Stop parsing PDFs line by line. Let Stock Titan surface the trial milestones, licensing terms, and insider moves that move ELEV.
Elevation Oncology, Inc. Schedule 13G/A discloses that Tang Capital entities and Kevin Tang beneficially own 3,115,000 shares of common stock, representing 4.997% of the class on a fully-diluted basis. The 3,115,000 shares are currently issuable upon exercise of warrants that are immediately exercisable and expire five years from issuance. The filing states the 62,338,729-share denominator used (59,223,729 outstanding as of May 9, 2025 plus 3,115,000 warrants). Voting and dispositive power over these shares is shared among Tang Capital Management, Tang Capital Partners, LP and Kevin Tang. The filing affirms these holdings are not for control purposes.
Several Frazier Life Sciences funds and named individuals filed a Schedule 13G/A reporting that they hold no beneficial ownership of Elevation Oncology common stock. Each Reporting Person discloses 0.00 shares and 0.0% of the class, with zero sole or shared voting power and zero sole or shared dispositive power. The statement includes a certification that the securities were not acquired for the purpose of changing or influencing control of the issuer.
The filing identifies the reporting entities as multiple Frazier Life Sciences partnerships and affiliated entities and names the Members as James N. Topper, Patrick J. Heron, Albert Cha, James Brush and Daniel Estes. A Joint Filing Agreement is incorporated by reference. Given the reported aggregate ownership of zero, this disclosure does not change the companys ownership or voting structure.
BML Investment Partners, L.P. has filed Amendment No. 1 to Schedule 13D regarding its prior position in Elevation Oncology, Inc. (ELEV). The filing states that, as of 23 July 2025, a Merger Agreement was consummated through a tender offer by an unaffiliated “Merger Sub” that purchased all outstanding shares of Elevation Oncology common stock. Following the closing, BML Investment Partners reports 0 shares beneficially owned, representing 0 % of the class.
• Voting and dispositive power: 0 shares sole or shared.
• Source of funds: “WC” (working capital) is listed, but no new capital was deployed as the position has been exited.
• No contracts, arrangements, or legal proceedings related to the securities are disclosed, and the reporting persons confirm no criminal or civil violations within the past five years.
The amendment principally serves to formally terminate BML’s reporting obligations by documenting its complete divestiture after the successful tender offer.
FAQ
What is the current stock price of Elevation Oncolo (ELEV)?
What is the market cap of Elevation Oncolo (ELEV)?
